Загрузка...
Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects
BACKGROUND: Macitentan is a clinically approved endothelin receptor antagonist for the treatment of pulmonary arterial hypertension (PAH). Increasing use of combination drug therapy in PAH means that it is important to recognize potential drug–drug interactions (DDIs) that could affect the efficacy...
Сохранить в:
| Опубликовано в: : | Clin Drug Investig |
|---|---|
| Главные авторы: | , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Springer International Publishing
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6842351/ https://ncbi.nlm.nih.gov/pubmed/31552642 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40261-019-00857-7 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|